Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of TAK-755 in acute ischemic stroke
CTR20261054Phase 2Active
- Sponsor
- Takeda
- Start
- May 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing TAK-755 with Placebo (2 arms). Primary endpoint: Proportion of participants with symptomatic intracranial hemorrhage. Started May 2026; status: active.
02
Drugs
Apadamtase alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20261054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261054.